Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib and tipifarnib in high-risk myelodysplastic syndrome
NL-OMON26222Phase 1Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Jun 2007
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bortezomib and tipifarnib in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) (6 cohorts), sponsored by Radboud University Medical Center. Primary endpoint: Safety. Started Jun 2007; status: recruiting.
02
Drugs
bortezomibtipifarnib
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NL-OMON26222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26222.